{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-022940","form_type":"8-K","ticker":"CYRX","cik":"0001124524","company_name":"Cryoport, Inc.","filed_at":"2026-03-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.567953+00:00","generated_at":"2026-05-15T21:59:47.922290+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cryoport FY2025 revenue $176.2M (+12% YoY) beats guidance; FY2026 outlook $190-194M","bullets":["FY2025 revenue $176.2M, up 12% YoY; Q4 revenue $45.5M, up 10% YoY.","Loss from continuing operations $34.0M; adjusted EBITDA from cont. ops -$5.8M (vs -$17.8M).","Commercial cell & gene therapy revenue $33.4M (+29% YoY); supported 760 clinical trials.","Life Sciences Services revenue $96.5M (+18%); BioStorage/BioServices up 22% to $18.4M.","Cash & investments $411.2M; repurchased 1.34M shares at avg $7.45 for $10.0M."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-022940","json":"https://secwatch.observer/filing/0001104659-26-022940.json","markdown":"https://secwatch.observer/filing/0001104659-26-022940.md","text":"https://secwatch.observer/filing/0001104659-26-022940.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1124524/000110465926022940/0001104659-26-022940-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1124524/000110465926022940/tm267876d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T21:59:47.922290+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}